{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:32:35Z","timestamp":1792297955995,"version":"4.4.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jaip.2023.04.054","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T11:56:54Z","timestamp":1683892614000},"page":"2642-2651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["The Management of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With Biologics"],"prefix":"10.1016","volume":"11","author":[{"given":"A.","family":"Wautlet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bachert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Desrosiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Hellings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju T.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2023.04.054_bib1","first-page":"S1","article-title":"Clinical practice guideline (update): adult sinusitis","volume":"152","author":"Rosenfeld","year":"2015","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaip.2023.04.054_bib2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/all.13042","article-title":"Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample","volume":"72","author":"Hirsch","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.04.054_bib3","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1398-9995.2011.02646.x","article-title":"Chronic rhinosinusitis in Europe\u2014an underestimated disease. A GA2LEN study","volume":"66","author":"Hastan","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.04.054_bib4","article-title":"White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA","volume":"3","author":"De Prins","year":"2022","journal-title":"Front Allergy"},{"key":"10.1016\/j.jaip.2023.04.054_bib5","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease","volume":"5","author":"Stevens","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.04.054_bib6","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.jaci.2013.02.002","article-title":"Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis","volume":"131","author":"Tan","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/000348940311200709","article-title":"Prevalence of nasal polyps in adults: the Sk\u00f6vde population-based study","volume":"112","author":"Johansson","year":"2003","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.jaip.2023.04.054_bib8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1398-9995.2005.00688.x","article-title":"Prevalence of nasal polyposis in France: a cross-sectional, case-control study","volume":"60","author":"Klossek","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.04.054_bib9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/jamaoto.2015.3142","article-title":"Prevalence and risk factors of chronic rhinosinusitus, allergic rhinitis, and nasal septal deviation: results of the Korean National Health and Nutrition Survey 2008\u20132012","volume":"142","author":"Ahn","year":"2016","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaip.2023.04.054_bib10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.anai.2018.02.005","article-title":"Age-related prevalence of chronic rhinosinusitis and nasal polyps and their relationships with asthma onset","volume":"120","author":"Won","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jaci.2018.12.986","article-title":"Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology","volume":"143","author":"Dietz de Loos","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4193\/Rhino11.256","article-title":"Prevalence of chronic rhinosinusitis in Sao Paulo","volume":"50","author":"Pilan","year":"2012","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2023.04.054_bib13","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaip.2018.10.014","article-title":"Clinical characteristics of patients with chronic rhinosinusitis without nasal polyps in an academic setting","volume":"7","author":"Benjamin","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.04.054_bib15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2500\/ajra.2014.28.4076","article-title":"A\u00a0comparative and descriptive study of asthma in chronic rhinosinusitis with nasal polyps","volume":"28","author":"H\u00e5kansson","year":"2014","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2023.04.054_bib16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cea.12880","article-title":"Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications","volume":"47","author":"Robinson","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2023.04.054_bib17","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jaci.2008.09.033","article-title":"Cigarette smoke combined with Toll-like receptor 3 signaling triggers exaggerated epithelial regulated upon activation, normal T-cell expressed and secreted\/CCL5 expression in chronic rhinosinusitis","volume":"122","author":"Yamin","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib18","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/lary.26548","article-title":"Smoking: an independent risk factor for lost productivity in chronic rhinosinusitis","volume":"127","author":"Campbell","year":"2017","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaip.2023.04.054_bib19","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/j.1398-9995.2011.02646.x","article-title":"Chronic rhinosinusitis in Europe\u2014an underestimated disease. A GA2LEN study","volume":"66","author":"Hastan","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.04.054_bib20","first-page":"110","article-title":"Allergenic profile of nasal polyposis","volume":"19","author":"Mu\u00f1oz del Castillo","year":"2009","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib21","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jaci.2013.01.028","article-title":"Genetics of chronic rhinosinusitis: state of the field and directions forward","volume":"131","author":"Hsu","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/alr.21469","article-title":"Familial risk of chronic rhinosinusitis with and without nasal polyposis: genetics or environment","volume":"5","author":"Oakley","year":"2015","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2023.04.054_bib23","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jaci.2023.01.004","article-title":"Genetics and epigenetics of chronic rhinosinusitis","volume":"151","author":"Lal","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2022.1048385","article-title":"Multiple reasons underlaying uncontrolled disease in the majority of chronic rhinosinusitis patients","volume":"3","author":"Viskens","year":"2022","journal-title":"Front Allergy"},{"key":"10.1016\/j.jaip.2023.04.054_bib25","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jaip.2022.01.039","article-title":"SWOT analysis of chronic rhinosinusitis care anno 2022","volume":"10","author":"Hellings","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.04.054_bib26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4193\/Rhin20.601","article-title":"Executive summary of EPOS 2020 including integrated care pathways","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2023.04.054_bib28","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.04.054_bib29","first-page":"85","article-title":"The EUFOREA pocket guide for chronic rhinosinusitis","volume":"61","author":"Hellings","year":"2023","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2023.04.054_bib30","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.04.054_bib31","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/cea.14194","article-title":"Improvement in patient-reported \"taste\" and association with smell in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS-24 and SINUS-52 trials","volume":"52","author":"Peters","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2023.04.054_bib32","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.04.054_bib33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/all.14906","article-title":"Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status","volume":"77","author":"Fujieda","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.04.054_bib34","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/alr.23108","article-title":"Dupilumab-related adverse events among patients with chronic rhinosinusitis with nasal polyposis","volume":"13","author":"Lee","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2023.04.054_bib35","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jaci.2013.01.043","article-title":"Chronic rhinosinusitis with nasal polyps is characterized by B-cell inflammation and EBV-induced protein 2 expression","volume":"131","author":"Hulse","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib36","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1067\/mai.2001.112374","article-title":"Total and specific IgE in nasal polyps is related to local eosinophilic inflammation","volume":"107","author":"Bachert","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib37","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib38","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.jaci.2017.07.013","article-title":"Anaphylaxis associated with omalizumab administration: risk factors and patient characteristics","volume":"140","author":"Lieberman","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib39","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib40","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1172\/JCI17974","article-title":"Anti\u2013IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics","volume":"112","author":"Flood-Page","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2023.04.054_bib41","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2023.04.054_bib42","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib43","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti\u2013IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.rmed.2016.01.003","article-title":"Reductions in eosinophil biomarkers by benralizumab in patients with asthma","volume":"111","author":"Pham","year":"2016","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2023.04.054_bib45","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib46","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.jaci.2021.12.759","article-title":"Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER)","volume":"149","author":"Gevaert","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib47","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/cea.14158","article-title":"Efficacy of an oral CRTH2 antagonist (AZD1981) in the treatment of chronic rhinosinusitis with nasal polyps in adults: a randomized controlled clinical trial","volume":"52","author":"Price","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2023.04.054_bib48","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2500\/aap.2021.42.210058","article-title":"Impact of type 2 targeting biologics on acute exacerbations of chronic rhinosinusitis","volume":"42","author":"Patel","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2023.04.054_bib49","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.04.054_bib50","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jaip.2021.09.030","article-title":"Appraisal of the real-world effectiveness of biologic therapies in aspirin-exacerbated respiratory disease","volume":"10","author":"Wangberg","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.04.054_bib51","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","article-title":"Omalizumab can inhibit respiratory reaction during aspirin desensitization","volume":"121","author":"Lang","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib52","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. a randomized controlled trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2023.04.054_bib53","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jaip.2021.01.031","article-title":"Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps","volume":"9","author":"Peters","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.04.054_bib54","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib55","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jaci.2022.10.026","article-title":"The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis","volume":"151","author":"Rank","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.04.054_bib56","first-page":"151","article-title":"State-of-the-art overview on biological treatment for CRSwNP","volume":"59","author":"Hellings","year":"2021","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2023.04.054_bib57","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/lary.26391","article-title":"Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis","volume":"127","author":"DeConde","year":"2017","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaip.2023.04.054_bib58","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/alr.22951","article-title":"Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"12","author":"Dharmarajan","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2023.04.054_bib59","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s00405-022-07813-w","article-title":"Olfaction in nasal polyp patients after Reboot surgery: an endotype-based prospective study","volume":"280","author":"Gomes","year":"2023","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.jaip.2023.04.054_bib60","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1007\/s00405-022-07470-z","article-title":"Reboot surgery for chronic rhinosinusitis with nasal polyposis: recurrence and smell kinetics","volume":"279","author":"Gomes","year":"2022","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.jaip.2023.04.054_bib61","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11882-017-0690-5","article-title":"Economics of chronic rhinosinusitis","volume":"17","author":"Rudmik","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2023.04.054_bib62","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1002\/lary.28648","article-title":"Cost utility analysis of dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"131","author":"Scangas","year":"2021","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaip.2023.04.054_bib63","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/alr.22936","article-title":"economic evaluation of dupilumab versus endoscopic sinus surgery for the treatment of chronic rhinosinusitis with nasal polyps","volume":"12","author":"Parasher","year":"2022","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823005391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823005391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:39:05Z","timestamp":1761975545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219823005391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":62,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2213219823005391"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2023.04.054","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Management of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With Biologics","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2023.04.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}